Symbols

DCTH

Delcath Systems·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About DCTH

Delcath Systems, Inc.

A company that offers a system to administers chemotherapy and other therapeutic agents for tumors

Industry

Healthcare Equipment and Supplies

Established Date

Listing Date

05/01/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

156

Fiscal Year Ends

12-31

Website

www.delcath.com

Security Type

Common stock

Office address

566 Queensbury Avenue, Queensbury, NY 12804

Business

Introduction

Delcath Systems, Inc., was incorporated in Delaware in August 1988. The company is an interventional oncology company focused on the treatment of primary and liver metastatic cancers. The Company's lead product, HEPZATOTM KIT (" HEPZATO "melphalan for Injection/liver Delivery System), is a drug/device combination product approved by the U.S. Food and Drug Administration (FDA) on August 14, 2023 for the treatment of adult patients with uveal melanoma with unresectable liver metastases, Liver metastases in this patient affect less than 50% of the liver, and there is no extrahepatic disease, or extrahepatic disease is limited to bones, lymph nodes, and subcutaneous tissue.

Company Financials

EPS

DCTH has released its 2025 Q4 earnings. EPS was reported at -0.05, versus the expected -0.08, beating expectations. The chart below visualizes how DCTH has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

DCTH has released its 2025 Q4 earnings report, with revenue of 20.73M, reflecting a YoY change of 37.27%, and net profit of -1.90M, showing a YoY change of 44.20%. The Sankey diagram below clearly presents DCTH's revenue sources and cost distribution.